Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
about
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewTwo Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus SerotypesAn adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypesA Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus MacaquesDengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue VirusIdentification of Mutated Cyclization Sequences That Permit Efficient Replication of West Nile Virus Genomes: Use in Safer Propagation of a Novel Vaccine CandidatePhase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult VolunteersIssues related to recent dengue vaccine development.Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.Bioinformatics in new generation flavivirus vaccines.Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study.A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.Dengue vaccines: state of the art.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysisNext-generation dengue vaccines: novel strategies currently under development.Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.Targeted mutagenesis as a rational approach to dengue virus vaccine development.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 studyEvaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus.Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profilesDengue vaccines for travelers.The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.Challenges for the formulation of a universal vaccine against dengue.The current position and the future perspectives of cervical cancer screening.Developing a dengue vaccine: progress and future challenges.Recent progress in dengue vaccine development.Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates?The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice.The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2.Unique challenges faced by the clinical evaluation of dengue vaccines.Social representations of human papillomavirus in Bogotá, Colombia.Cervical cytology profile of infertility patients in Abakaliki, South-eastern Nigeria.
P2860
Q26700078-E1A13C06-EECF-4F80-8211-4E9FFB7B1A48Q27478075-9798E46E-0A62-49BA-8F0B-8C1174575FF3Q27478104-D7A005FC-A5F0-41E6-B9CA-479137022B37Q27484994-78F61ADD-4A15-48A1-9638-4700A93FAB49Q27485404-1E2382C3-10AF-49F1-9831-D240AA6CAA6BQ27486406-73DE2E9D-5614-4CB1-9C54-CBCA7C9F378DQ27486407-71BE1ADE-A3DA-4716-B487-AD11D46335A3Q27490989-AE51426C-BDE9-4E12-941F-923EB88A689BQ30395396-BF38CFB0-93C5-4FFA-81AF-E8494B0754B3Q33699057-06D21E7C-44EA-4BA1-8C52-ECF14291951EQ33743890-5FA4811A-DC30-4771-A7E4-FCB3E01E279CQ33839001-0376EA97-B246-405B-8E3E-1ACB583A1A48Q33930720-5AAA2607-0A26-44A1-9876-909EAB111ADCQ33988937-F27AA4D4-5500-4DAF-AF17-10EB3F507D85Q34109652-4D2C9AC5-6367-4754-9426-B94B79FECA8BQ34202440-5A089850-0BCD-43FA-8C77-48DB019579E7Q34306877-8A9E33DF-F304-433D-B6BE-B521270EFE55Q34423720-45C208EB-018D-4815-8C55-FA22902F4B1EQ35491639-713F9F41-C620-4007-A9F0-0A62A5ED9C9AQ35624552-7F6C9354-C68E-4CB0-9424-C11E7EE1989FQ35781300-06CA6FC2-ED57-4D0D-8F80-4BA9C03B8346Q36118259-CE1DD991-7E78-43AA-819D-2624CB15FC4EQ36288109-F627AC5A-916A-49F3-8B65-20CC4565C29DQ37120632-0770DF1E-1C4D-4451-8FB1-3D9EE59ACCC3Q37184768-2FFDA3D5-8156-41BF-98C7-A9E2B1966204Q37194772-DAD8ECA0-6D8C-4938-B6C8-312FC142666BQ37903445-D83EDE94-166D-42A0-8ADC-95B90BFA9DC2Q38121757-8A9A5108-21FA-4DEA-8596-D04E8AEAEE70Q38168923-8F1E0017-4CD7-4331-A5DD-FBD0575BFB11Q38201151-F676D36E-EAE0-4E0C-86F1-CA9D629BF0D7Q38303232-1472B577-8F84-47A9-AEE7-39217802367DQ38618056-13885BEA-7BC5-4E7B-9B04-4080C1DAB352Q40295653-6BC90549-6E3B-4883-9B22-1DF1E631FC6EQ40338292-8CDF2D1A-7DBE-4EC4-BE21-211D30A35C13Q43034442-6A0877EB-B6ED-4329-AF56-019B445E5D72Q47230014-8AF85C6B-07A7-444E-8F8F-098BF4ECBA89Q50598257-470603B6-2A41-4F23-850C-AF64A29EBF73
P2860
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunogenicity and safety of t ...... in healthy Australian adults.
@en
type
label
Immunogenicity and safety of t ...... in healthy Australian adults.
@en
prefLabel
Immunogenicity and safety of t ...... in healthy Australian adults.
@en
P2093
P1433
P1476
Immunogenicity and safety of t ...... s in healthy Australian adults
@en
P2093
Jean-François Saluzzo
Michael Nissen
Peter Nasveld
Remi Forrat
Sutee Yoksan
P304
P356
10.1016/J.VACCINE.2005.09.029
P407
P577
2005-09-23T00:00:00Z